Dupilumab

Excerpt

Dupilumab is an injectable prescription medication administered subcutaneously to treat severe and refractory forms of atopic dermatitis. The US Food and Drug Administration (FDA) approved the medication in April 2017 to treat moderate-to-severe, resistant, atopic dermatitis unresponsive to conventional therapy, including topical corticosteroids. Dupilumab is also used as a maintenance treatment for asthma and chronic rhinosinusitis with nasal polyposis in adults and children, in conjunction with other medications.